Trial reportPloS one2026
Ring-augmented versus conventional one-anastomosis gastric bypass: Perioperative and short-term results in the randomized controlled RiMini trial.
Trial report in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeRecurrent weight gain remains a challenge in metabolic bariatric surgery (MBS). Recent publications focused on ring-augmented Roux-en-Y gastric bypass (RYGB) and ring-augmented sleeve gastrectomy (SG), but few studies have addressed the potential of ring-augmentation for one-anastomosis gastric bypass (OAGB).
objectivesThe RiMini trial is a single-center randomized controlled trial that investigates the difference in long-term weight reduction, associated medical comorbidities, quality of life, and procedure-related adverse events of ring-augmented OAGB compared to conventional OAGB in adult patients eligible for primary OAGB. This analysis reports the trial's short-term outcomes, including the peri-operative safety of the procedure, short-term adverse events, and weight outcomes at one year postoperatively.
methodsBetween July 2022 and December 2023, a total of 214 patients (107 per group) underwent either ring-augmented or conventional OAGB after randomization. Peri- and postoperative adverse events, and total and excess weight loss percentages (%TWL and %EWL) were assessed by intention-to-treat and per-protocol analysis.
resultsAt baseline, there were no differences between groups regarding age, gender, and body mass index (BMI). Mean operation time was 51 minutes (±13) in both groups (p = 0.84). One patient in each group experienced a perioperative complication (p = 1.00; 0.9%). There was no significant difference in postoperative minor (Clavien Dindo (CD) 1-2) (p = 0.68) or major (CD3-5) (p = 0.77) complications. In the first year, two Minimizer rings were electively removed at patients' request, without observed complications related to the ring. At one year, mean BMI was comparable in both groups (28 kg/m2). There was no statistically significant difference between ring-augmented and conventional OAGB in %TWL (33% vs 31%; p = 0.30), and %EWL (86% vs 84%; p = 0.45).
conclusionsThe 1-year analyses of the RiMini trial showed that ring-augmented OAGB is comparable in safety to conventional OAGB. At 1 year, there was no statistically significant difference in weight loss between the groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.